Article
WaveTec Vision has secured $15.9 million in Series D financing from existing and new investors.
Aliso Viejo, CA-WaveTec Vision has secured $15.9 million in Series D financing from existing and new investors.
The company will use the funds to expand commercialization of its intraoperative wavefront aberrometer (ORange), demonstrate further the clinical efficacy of the technology, and increase its infrastructure, said Tom Frinzi, WaveTec chief executive officer.
The Series D financing was led by existing investor Versant Ventures, with participation from existing investors Accuitive Medical Ventures and De Novo Ventures. New investor Gund Investment Corporation also participated in the funding.
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.